Company news

Sight Sciences, Inc. news in 2022

Sight Sciences, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Sight Sciences Reports Third Quarter 2022 Financial Results

November 9, 2022

Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure

November 2, 2022

Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022

October 19, 2022

Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

September 28, 2022

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®

September 12, 2022

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

August 22, 2022

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

August 15, 2022

Sight Sciences Reports Second Quarter 2022 Financial Results

August 10, 2022

Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

July 27, 2022

Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

July 18, 2022

Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data

May 30, 2022

Sight Sciences Reports First Quarter 2022 Financial Results

May 9, 2022

Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

April 19, 2022

Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022

April 13, 2022

Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

March 23, 2022

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

March 23, 2022

Sight Sciences Announces Appointment of Brenda Becker to Board of Directors

March 15, 2022

Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting

March 1, 2022

Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

February 16, 2022

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

January 9, 2022

Calls in 2022

Decks in 2022